PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33912510-0 2021 Combined alpha-methylacyl-CoA racemase inhibition and docetaxel treatment reduce cell proliferation and decrease expression of heat shock protein 27 in androgen receptor-variant-7-positive prostate cancer cells. Docetaxel 54-63 androgen receptor Homo sapiens 152-169 33912510-5 2021 The Western blotting analysis revealed that both AR and ARV7 expression were significantly decreased with the use of charcoal-stripped serum following AMACR inhibition and docetaxel treatment. Docetaxel 172-181 androgen receptor Homo sapiens 49-51 33912510-7 2021 Conclusion: Using cell proliferation and Western blot analysis, we demonstrated that AMACR inhibition and docetaxel treatment, under androgen deprivation conditions, significantly reduced the proliferation of ARV7 positive cancer cells and decreased the levels of AR and ARV7 expression, possibly via downregulation of heat shock protein 27. Docetaxel 106-115 androgen receptor Homo sapiens 209-211 32989230-0 2020 Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer. Docetaxel 37-46 androgen receptor Homo sapiens 0-17 33428943-0 2021 Androgen receptor splicing variant 7(ARV7) inhibits docetaxel sensitivity by inactivating the spindle assembly checkpoint. Docetaxel 52-61 androgen receptor Homo sapiens 0-17 33428943-2 2021 Recently, aberrant androgen receptor (AR) signaling, including expression of the constitutively active ARV7, was reported to contribute to DTX resistance. Docetaxel 139-142 androgen receptor Homo sapiens 19-36 33428943-2 2021 Recently, aberrant androgen receptor (AR) signaling, including expression of the constitutively active ARV7, was reported to contribute to DTX resistance. Docetaxel 139-142 androgen receptor Homo sapiens 38-40 33428943-10 2021 In sum, our work identified a novel role of ARV7 in promoting DTX resistance and offering a potential path to combat DTX resistance related to abnormal activation of the AR signaling and mitotic dysregulation. Docetaxel 62-65 androgen receptor Homo sapiens 44-46 33428943-10 2021 In sum, our work identified a novel role of ARV7 in promoting DTX resistance and offering a potential path to combat DTX resistance related to abnormal activation of the AR signaling and mitotic dysregulation. Docetaxel 117-120 androgen receptor Homo sapiens 44-46 32989230-3 2020 We studied whether testosterone and AR signalling interferes with docetaxel treatment efficacy in castration-resistant prostate cancer (CRPC). Docetaxel 66-75 androgen receptor Homo sapiens 36-38 32989230-6 2020 Irrespective of docetaxel-induced tubulin stabilisation, AR signalling by testosterone counteracted docetaxel efficacy. Docetaxel 100-109 androgen receptor Homo sapiens 57-59 32989230-7 2020 AR-pathway activation could also reverse long-term tumour regression by docetaxel treatment in vivo. Docetaxel 72-81 androgen receptor Homo sapiens 0-2 32989230-8 2020 These results indicate that to optimise docetaxel efficacy, androgen levels and AR signalling need to be suppressed. Docetaxel 40-49 androgen receptor Homo sapiens 80-82 32989230-9 2020 This study lends evidence for continued maximum suppression of AR signalling by combining targeted therapeutics with docetaxel in CRPC. Docetaxel 117-126 androgen receptor Homo sapiens 63-65 32449811-0 2020 Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals. Docetaxel 0-9 androgen receptor Homo sapiens 131-148 32449811-9 2020 RESULTS: We found that docetaxel could suppress the immunotherapy efficacy of NK cells toward CRPC cells via the androgen receptor (AR)-lectin-like transcript 1 (LLT1) signals in vitro. Docetaxel 23-32 androgen receptor Homo sapiens 113-130 32449811-9 2020 RESULTS: We found that docetaxel could suppress the immunotherapy efficacy of NK cells toward CRPC cells via the androgen receptor (AR)-lectin-like transcript 1 (LLT1) signals in vitro. Docetaxel 23-32 androgen receptor Homo sapiens 132-134 32449811-10 2020 Analysis of the mechanism revealed that docetaxel functioned through increasing AR to upregulate LLT1 expression in CRPC cells. Docetaxel 40-49 androgen receptor Homo sapiens 80-82 32449811-12 2020 Furthermore, targeting AR with ASC-J9 or blocking LL1 by anti-human LLT1 monoclonal antibody could reverse the suppressive effect of docetaxel on the immunotherapy efficacy of NK cells toward CRPC cells. Docetaxel 133-142 androgen receptor Homo sapiens 23-25 32449811-13 2020 CONCLUSIONS: We concluded that chemotherapy agent docetaxel could increase AR that transcriptionally regulated the expression of NK inhibitory ligand LLT1 on CRPC cells. Docetaxel 50-59 androgen receptor Homo sapiens 75-77 32274540-5 2020 RESULTS: The androgen receptor (AR)-targeting agents abiraterone and enzalutamide significantly prolong overall survival before and after docetaxel therapy. Docetaxel 138-147 androgen receptor Homo sapiens 13-30 32274540-5 2020 RESULTS: The androgen receptor (AR)-targeting agents abiraterone and enzalutamide significantly prolong overall survival before and after docetaxel therapy. Docetaxel 138-147 androgen receptor Homo sapiens 32-34 32373521-2 2020 We report a case who had been positive for androgen receptor splice variant 7 in CTCs before docetaxel, and was subsequently treated with abiraterone rechallenge because of the negative conversion of androgen receptor splice variant 7 following docetaxel. Docetaxel 93-102 androgen receptor Homo sapiens 43-60 32174789-0 2020 Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways. Docetaxel 19-28 androgen receptor Homo sapiens 63-80 31053766-2 2020 Docetaxel impairs microtubules, has androgen receptor (AR) inhibitory effects and is used in both the castration resistant and sensitive settings, where androgen dynamics may impact outcome. Docetaxel 0-9 androgen receptor Homo sapiens 36-53 31053766-2 2020 Docetaxel impairs microtubules, has androgen receptor (AR) inhibitory effects and is used in both the castration resistant and sensitive settings, where androgen dynamics may impact outcome. Docetaxel 0-9 androgen receptor Homo sapiens 55-57 32174789-11 2020 It was found that docetaxel-resistant subclones had stronger activation of androgen receptor and PI3K/Akt pathway, more remarkable mesenchymal and stem-like cell phenotypes, and more P-gp expression than that of parental cells. Docetaxel 18-27 androgen receptor Homo sapiens 75-92 30301829-2 2019 The presence or absence of androgen receptor (AR) splice variants, AR-V7 and ARv567es, in mCRPC patient circulating tumor cells (CTC) may be associated with taxane treatment outcomes.Experimental Design: A novel digital droplet PCR (ddPCR) assay assessed AR-splice variant expression in CTCs from patients receiving docetaxel or cabazitaxel in TAXYNERGY (NCT01718353). Docetaxel 316-325 androgen receptor Homo sapiens 46-48 31200322-1 2019 BACKGROUND: Plasma androgen receptor (AR) copy number status has been identified as a potential biomarker of response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel or the AR-targeted therapies abiraterone or enzalutamide. Docetaxel 201-210 androgen receptor Homo sapiens 19-36 31200322-1 2019 BACKGROUND: Plasma androgen receptor (AR) copy number status has been identified as a potential biomarker of response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel or the AR-targeted therapies abiraterone or enzalutamide. Docetaxel 201-210 androgen receptor Homo sapiens 38-40 30864701-2 2019 Given the complexity of prostate cancer and the pressing challenge of chemoresistance, the current study was conducted to investigate the effect of docetaxel (Doc) on androgen receptor (AR)-dependent and AR-independent prostate cancers cells. Docetaxel 148-157 androgen receptor Homo sapiens 167-184 30864701-2 2019 Given the complexity of prostate cancer and the pressing challenge of chemoresistance, the current study was conducted to investigate the effect of docetaxel (Doc) on androgen receptor (AR)-dependent and AR-independent prostate cancers cells. Docetaxel 148-157 androgen receptor Homo sapiens 186-188 30864701-2 2019 Given the complexity of prostate cancer and the pressing challenge of chemoresistance, the current study was conducted to investigate the effect of docetaxel (Doc) on androgen receptor (AR)-dependent and AR-independent prostate cancers cells. Docetaxel 159-162 androgen receptor Homo sapiens 167-184 30864701-2 2019 Given the complexity of prostate cancer and the pressing challenge of chemoresistance, the current study was conducted to investigate the effect of docetaxel (Doc) on androgen receptor (AR)-dependent and AR-independent prostate cancers cells. Docetaxel 159-162 androgen receptor Homo sapiens 186-188 31515456-9 2019 Low AR-active tumors were predicted to be more sensitive to poly (ADP-ribose) polymerase inhibition, platinum chemotherapy, and radiotherapy, and less sensitive to docetaxel and androgen-deprivation therapy. Docetaxel 164-173 androgen receptor Homo sapiens 4-6 30248372-0 2019 Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9 led to increase docetaxel sensitivity via suppressing the p21 expression. Docetaxel 90-99 androgen receptor Homo sapiens 14-31 30248372-3 2019 Here we found docetaxel treatment might have an adverse effect of increasing the androgen receptor (AR) protein level in the CRPC cells, and combining docetaxel with anti-AR therapy using AR-shRNA or the AR degradation enhancer ASC-J9 may increase docetaxel sensitivity to better suppress the CRPC cell growth. Docetaxel 14-23 androgen receptor Homo sapiens 81-98 30248372-3 2019 Here we found docetaxel treatment might have an adverse effect of increasing the androgen receptor (AR) protein level in the CRPC cells, and combining docetaxel with anti-AR therapy using AR-shRNA or the AR degradation enhancer ASC-J9 may increase docetaxel sensitivity to better suppress the CRPC cell growth. Docetaxel 14-23 androgen receptor Homo sapiens 100-102 30248372-4 2019 Mechanism dissection found docetaxel might have the adverse effect of increasing the AR protein stability via suppressing the AR ubiquitination due to the increased AR phosphorylation. Docetaxel 27-36 androgen receptor Homo sapiens 85-87 30248372-4 2019 Mechanism dissection found docetaxel might have the adverse effect of increasing the AR protein stability via suppressing the AR ubiquitination due to the increased AR phosphorylation. Docetaxel 27-36 androgen receptor Homo sapiens 126-128 30248372-4 2019 Mechanism dissection found docetaxel might have the adverse effect of increasing the AR protein stability via suppressing the AR ubiquitination due to the increased AR phosphorylation. Docetaxel 27-36 androgen receptor Homo sapiens 126-128 30248372-6 2019 Preclinical studies with in vitro cells lines also demonstrated that targeting AR with ASC-J9 led to suppressing the AR-increased p21 expression to improve the docetaxel sensitivity in the CRPC cells that already developed docetaxel resistance. Docetaxel 161-170 androgen receptor Homo sapiens 79-81 30248372-6 2019 Preclinical studies with in vitro cells lines also demonstrated that targeting AR with ASC-J9 led to suppressing the AR-increased p21 expression to improve the docetaxel sensitivity in the CRPC cells that already developed docetaxel resistance. Docetaxel 161-170 androgen receptor Homo sapiens 118-120 30248372-6 2019 Preclinical studies with in vitro cells lines also demonstrated that targeting AR with ASC-J9 led to suppressing the AR-increased p21 expression to improve the docetaxel sensitivity in the CRPC cells that already developed docetaxel resistance. Docetaxel 224-233 androgen receptor Homo sapiens 79-81 30248372-6 2019 Preclinical studies with in vitro cells lines also demonstrated that targeting AR with ASC-J9 led to suppressing the AR-increased p21 expression to improve the docetaxel sensitivity in the CRPC cells that already developed docetaxel resistance. Docetaxel 224-233 androgen receptor Homo sapiens 118-120 30248372-0 2019 Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9 led to increase docetaxel sensitivity via suppressing the p21 expression. Docetaxel 90-99 androgen receptor Homo sapiens 33-35 30248372-0 2019 Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9 led to increase docetaxel sensitivity via suppressing the p21 expression. Docetaxel 90-99 androgen receptor Homo sapiens 42-44 30773204-7 2019 In an exploratory analysis of mCRPC patients receiving first-line therapies, a significant interaction was observed between plasma AR and docetaxel versus abiraterone/enzalutamide for OS (HR=0.16, 95% CI=0.06-0.46, p<0.001) and PFS (HR=0.31, 95% CI=0.12-0.80, p=0.02). Docetaxel 138-147 androgen receptor Homo sapiens 131-133 30773204-9 2019 These data suggest that AR-normal patients should receive abiraterone/enzalutamide and AR-gained could benefit from docetaxel. Docetaxel 116-125 androgen receptor Homo sapiens 24-26 30773204-9 2019 These data suggest that AR-normal patients should receive abiraterone/enzalutamide and AR-gained could benefit from docetaxel. Docetaxel 116-125 androgen receptor Homo sapiens 87-89 30773204-12 2019 We showed that plasma AR normal favored hormonal treatment, whilst plasma AR-gained patients may have had a longer response to docetaxel, suggesting that plasma AR status could be a useful treatment selection biomarker. Docetaxel 127-136 androgen receptor Homo sapiens 74-76 30773204-12 2019 We showed that plasma AR normal favored hormonal treatment, whilst plasma AR-gained patients may have had a longer response to docetaxel, suggesting that plasma AR status could be a useful treatment selection biomarker. Docetaxel 127-136 androgen receptor Homo sapiens 74-76 30519360-15 2018 The SDA/DOC combination down regulated testosterone (T)-induced AR and troglitazone-induced PPARgamma protein expression when compared to using the drugs singly. Docetaxel 8-11 androgen receptor Homo sapiens 64-66 29725990-7 2018 RESULTS: The AdnaTest detected AR mRNA in three-quarters of CTC-positive samples taken at the time of CRPC diagnosis and after the third docetaxel cycle. Docetaxel 138-147 androgen receptor Homo sapiens 32-34 29275450-1 2018 BACKGROUND: To investigate whether the response to an androgen receptor-axis-targeted (ARAT) agent is associated with the efficacy of subsequent docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients. Docetaxel 145-154 androgen receptor Homo sapiens 54-71 30341281-0 2018 A functional genomics screen reveals a strong synergistic effect between docetaxel and the mitotic gene DLGAP5 that is mediated by the androgen receptor. Docetaxel 73-82 androgen receptor Homo sapiens 135-152 30341281-10 2018 In contrast, the knockdown of the androgen receptor by siRNA appears to assist cells to progress through metaphase in to anaphase, even in the presence of docetaxel. Docetaxel 155-164 androgen receptor Homo sapiens 34-51 29158269-3 2018 Being closely related to the AR, the glucocorticoid receptor (GR) has been suggested to play a role in enzalutamide and docetaxel resistance. Docetaxel 120-129 androgen receptor Homo sapiens 29-31 29110971-1 2017 Two new drugs, the CYP17 inhibitor abiraterone acetate and the androgen receptor (AR) antagonist enzalutamide, have recently shown to prolong OS prior chemotherapy or in docetaxel treated mCRPC patients, using steroidal therapy or placebo as control group. Docetaxel 170-179 androgen receptor Homo sapiens 63-80 29276148-4 2018 The recent STAMPEDE and CHAARTED trials showed that docetaxel in combination with ADT increased survival in hormone sensitive prostate cancer patients, suggesting cross-talk between AR signaling and chemotherapy efficacy. Docetaxel 52-61 androgen receptor Homo sapiens 27-29 29110971-1 2017 Two new drugs, the CYP17 inhibitor abiraterone acetate and the androgen receptor (AR) antagonist enzalutamide, have recently shown to prolong OS prior chemotherapy or in docetaxel treated mCRPC patients, using steroidal therapy or placebo as control group. Docetaxel 170-179 androgen receptor Homo sapiens 82-84 29164346-1 2017 The objective of this study was to investigate the impact of prior treatment with androgen receptor-axis-targeted (ARAT) agents, abiraterone acetate (AA) and enzalutamide (Enz), on the activity of subsequently introduced docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel 221-230 androgen receptor Homo sapiens 82-99 27979512-0 2017 Re: Resistance to Docetaxel in Prostate Cancer is Associated with Androgen Receptor Activation and Loss of KDM5D Expression. Docetaxel 18-27 androgen receptor Homo sapiens 66-83 28063845-1 2017 BACKGROUND: The objective of this study was to compare the efficacies of sequential therapies with novel androgen receptor-axis-targeted (ARAT) agents in patients with docetaxel-naive metastatic castration-resistant prostate cancer (mCRPC). Docetaxel 168-177 androgen receptor Homo sapiens 105-122 28472366-6 2017 AR mutations [2105T>A (p.L702H) and 2632A>G (p.T878A)] were observed in eight (11%) post-docetaxel but no chemotherapy-naive abiraterone-treated patients and were also associated with worse OS (HR 3.26; 95% CI 1.47-not reached; P = 0.004). Docetaxel 95-104 androgen receptor Homo sapiens 0-2 25937426-17 2016 BACKGROUND: The androgen receptor inhibitor enzalutamide is approved for the treatment of metastatic castration-resistant prostate cancer that has progressed on docetaxel. Docetaxel 161-170 androgen receptor Homo sapiens 16-33 26858312-1 2016 PURPOSE: Preclinical evidence suggests that both docetaxel and enzalutamide target androgen receptor translocation and signaling. Docetaxel 49-58 androgen receptor Homo sapiens 83-100 27185910-0 2016 Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Docetaxel 14-23 androgen receptor Homo sapiens 62-79 27185910-4 2016 This finding suggests that there is an interaction between AR signaling activity and docetaxel sensitivity. Docetaxel 85-94 androgen receptor Homo sapiens 59-61 27185910-5 2016 Here we demonstrate that the prostate cancer cell lines LNCaP and LAPC4 display markedly different sensitivity to docetaxel with AR activation, and RNA-seq analysis of these cell lines identified KDM5D (lysine-specific demethylase 5D) encoded on the Y chromosome as a potential mediator of this sensitivity. Docetaxel 114-123 androgen receptor Homo sapiens 129-131 27185910-8 2016 Attenuating KDM5D expression dysregulates AR signaling, resulting in docetaxel insensitivity. Docetaxel 69-78 androgen receptor Homo sapiens 42-44 26692530-11 2015 Because the CEP57-induced microtubule stabilization had no detectable effect on AR nuclear translocation, our results furthermore suggest that microtubule-targeting therapeutics used in advanced prostate cancer such as docetaxel may have modes of action that are at least in part independent of AR transport inhibition. Docetaxel 219-228 androgen receptor Homo sapiens 295-297 26215602-1 2016 Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Docetaxel 90-99 androgen receptor Homo sapiens 14-31 26483423-6 2016 The capability of the GR antagonists (RU-486 and cyproterone acetate) to revert docetaxel resistance was investigated and revealed significant resensitization of docetaxel-resistant PCa cells for docetaxel treatment in a dose- and time-dependent manner, in which a complete restoration of docetaxel sensitivity was achieved in both androgen receptor (AR)-negative and AR-positive cell lines. Docetaxel 162-171 androgen receptor Homo sapiens 332-349 26483423-6 2016 The capability of the GR antagonists (RU-486 and cyproterone acetate) to revert docetaxel resistance was investigated and revealed significant resensitization of docetaxel-resistant PCa cells for docetaxel treatment in a dose- and time-dependent manner, in which a complete restoration of docetaxel sensitivity was achieved in both androgen receptor (AR)-negative and AR-positive cell lines. Docetaxel 162-171 androgen receptor Homo sapiens 351-353 26483423-6 2016 The capability of the GR antagonists (RU-486 and cyproterone acetate) to revert docetaxel resistance was investigated and revealed significant resensitization of docetaxel-resistant PCa cells for docetaxel treatment in a dose- and time-dependent manner, in which a complete restoration of docetaxel sensitivity was achieved in both androgen receptor (AR)-negative and AR-positive cell lines. Docetaxel 162-171 androgen receptor Homo sapiens 368-370 26483423-6 2016 The capability of the GR antagonists (RU-486 and cyproterone acetate) to revert docetaxel resistance was investigated and revealed significant resensitization of docetaxel-resistant PCa cells for docetaxel treatment in a dose- and time-dependent manner, in which a complete restoration of docetaxel sensitivity was achieved in both androgen receptor (AR)-negative and AR-positive cell lines. Docetaxel 162-171 androgen receptor Homo sapiens 332-349 26483423-6 2016 The capability of the GR antagonists (RU-486 and cyproterone acetate) to revert docetaxel resistance was investigated and revealed significant resensitization of docetaxel-resistant PCa cells for docetaxel treatment in a dose- and time-dependent manner, in which a complete restoration of docetaxel sensitivity was achieved in both androgen receptor (AR)-negative and AR-positive cell lines. Docetaxel 162-171 androgen receptor Homo sapiens 351-353 26483423-6 2016 The capability of the GR antagonists (RU-486 and cyproterone acetate) to revert docetaxel resistance was investigated and revealed significant resensitization of docetaxel-resistant PCa cells for docetaxel treatment in a dose- and time-dependent manner, in which a complete restoration of docetaxel sensitivity was achieved in both androgen receptor (AR)-negative and AR-positive cell lines. Docetaxel 162-171 androgen receptor Homo sapiens 368-370 26483423-6 2016 The capability of the GR antagonists (RU-486 and cyproterone acetate) to revert docetaxel resistance was investigated and revealed significant resensitization of docetaxel-resistant PCa cells for docetaxel treatment in a dose- and time-dependent manner, in which a complete restoration of docetaxel sensitivity was achieved in both androgen receptor (AR)-negative and AR-positive cell lines. Docetaxel 162-171 androgen receptor Homo sapiens 332-349 26483423-6 2016 The capability of the GR antagonists (RU-486 and cyproterone acetate) to revert docetaxel resistance was investigated and revealed significant resensitization of docetaxel-resistant PCa cells for docetaxel treatment in a dose- and time-dependent manner, in which a complete restoration of docetaxel sensitivity was achieved in both androgen receptor (AR)-negative and AR-positive cell lines. Docetaxel 162-171 androgen receptor Homo sapiens 351-353 26483423-6 2016 The capability of the GR antagonists (RU-486 and cyproterone acetate) to revert docetaxel resistance was investigated and revealed significant resensitization of docetaxel-resistant PCa cells for docetaxel treatment in a dose- and time-dependent manner, in which a complete restoration of docetaxel sensitivity was achieved in both androgen receptor (AR)-negative and AR-positive cell lines. Docetaxel 162-171 androgen receptor Homo sapiens 368-370 26401448-6 2015 Treatment of the tumors with the taxane docetaxel showed that the drug inhibited tumor growth of the LuCaP 86.2 cells but not of the LuCaP 23.1 cells, indicating that expression of splice variants of the AR can affect sensitivity to docetaxel. Docetaxel 40-49 androgen receptor Homo sapiens 204-206 25995342-10 2015 Combination of bicalutamide with docetaxel had a significant antitumor effect in both AR-positive and AR-negative docetaxel-resistant xenograft models, suggesting that bicalutamide desensitizes docetaxel-resistant cells to docetaxel treatment independent of AR status. Docetaxel 33-42 androgen receptor Homo sapiens 86-88 25995342-10 2015 Combination of bicalutamide with docetaxel had a significant antitumor effect in both AR-positive and AR-negative docetaxel-resistant xenograft models, suggesting that bicalutamide desensitizes docetaxel-resistant cells to docetaxel treatment independent of AR status. Docetaxel 33-42 androgen receptor Homo sapiens 102-104 25995342-10 2015 Combination of bicalutamide with docetaxel had a significant antitumor effect in both AR-positive and AR-negative docetaxel-resistant xenograft models, suggesting that bicalutamide desensitizes docetaxel-resistant cells to docetaxel treatment independent of AR status. Docetaxel 33-42 androgen receptor Homo sapiens 102-104 26401448-6 2015 Treatment of the tumors with the taxane docetaxel showed that the drug inhibited tumor growth of the LuCaP 86.2 cells but not of the LuCaP 23.1 cells, indicating that expression of splice variants of the AR can affect sensitivity to docetaxel. Docetaxel 233-242 androgen receptor Homo sapiens 204-206 26093899-5 2015 Shifting the current paradigm is a growing evidence to indicate that Docetaxel can effectively target the AR signaling axis by blocking its nuclear translocation and transcriptional activity in androgen-sensitive and castration-resistant prostate cancer cells, implicating a new mechanism of cross-resistance between microtubule-targeting chemotherapy and antiandrogen therapies. Docetaxel 69-78 androgen receptor Homo sapiens 106-108 25484141-0 2015 Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Docetaxel 90-99 androgen receptor Homo sapiens 14-31 25484141-2 2015 However, concerns regarding cross-resistance between the taxanes docetaxel and cabazitaxel and these AR-targeted agents have arisen, and the optimal drug treatment sequence is unknown. Docetaxel 65-74 androgen receptor Homo sapiens 101-103 25484141-6 2015 Docetaxel inhibited tumor growth, AR nuclear localization, and AR-regulated gene expression in enzalutamide-naive tumors, but did not in enzalutamide-resistant tumors, demonstrating in vivo cross-resistance. Docetaxel 0-9 androgen receptor Homo sapiens 34-36 25484141-6 2015 Docetaxel inhibited tumor growth, AR nuclear localization, and AR-regulated gene expression in enzalutamide-naive tumors, but did not in enzalutamide-resistant tumors, demonstrating in vivo cross-resistance. Docetaxel 0-9 androgen receptor Homo sapiens 63-65 25484141-8 2015 These findings demonstrate that the AR pathway is able to confer in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in CRPC. Docetaxel 115-124 androgen receptor Homo sapiens 36-38 25432105-6 2014 Our findings demonstrate that there was no significant effect on the androgen-mediated nuclear transport of AR variants and AR transcriptional activity by Docetaxel. Docetaxel 155-164 androgen receptor Homo sapiens 124-126 25569176-3 2015 Enzalutamide is a potent AR antagonist that was initially approved in 2012 for men with CRPC who had previously failed chemotherapy treatment with docetaxel. Docetaxel 147-156 androgen receptor Homo sapiens 25-27 25432105-7 2014 The therapeutic response to Docetaxel was enhanced by inhibition of the NTD of AR (by EPI) through cycling of epithelial-mesenchymal-transition (EMT) to mesenchymal-epithelial-transition (MET) among prostate cancer epithelial cells. Docetaxel 28-37 androgen receptor Homo sapiens 79-81 24739897-1 2014 BACKGROUND: The androgen receptor inhibitor enzalutamide is approved for the treatment of metastatic castration-resistant prostate cancer that has progressed on docetaxel. Docetaxel 161-170 androgen receptor Homo sapiens 16-33 24260253-4 2013 Docetaxel (Doc) and paclitaxel (Pac) agents showed different effects on LNCaP and LNb4 evidenced by alteration in the protein and mRNA levels of c-jun, AR and PSA. Docetaxel 0-9 androgen receptor Homo sapiens 152-154 24200698-10 2013 Furthermore, docetaxel and cabazitaxel inhibited AR nuclear translocation, which was also observed for abiraterone and enzalutamide. Docetaxel 13-22 androgen receptor Homo sapiens 49-51 24965392-11 2014 Docetaxel and cabazitaxel, the standard chemotherapy of mCRPC, are the treatment of choice when androgen-independent prostate cancer cells are selected (as supported by the lurker cell pathway).The correct and rational use of all these drugs may delay by months or even years the need to administer chemotherapy in patients with mCRPC but some AR targeted therapies may impair the subsequent response to chemotherapy. Docetaxel 0-9 androgen receptor Homo sapiens 344-346 24260253-4 2013 Docetaxel (Doc) and paclitaxel (Pac) agents showed different effects on LNCaP and LNb4 evidenced by alteration in the protein and mRNA levels of c-jun, AR and PSA. Docetaxel 0-3 androgen receptor Homo sapiens 152-154 34672379-0 2022 Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer. Docetaxel 78-87 androgen receptor Homo sapiens 0-17 23566222-11 2013 CONCLUSIONS: Interrupting Vav3 signaling enhances docetaxel-induced apoptosis in LNCaP cells under chronic hypoxia by inhibiting the PI3K/Akt, ERK, and AR signaling pathways. Docetaxel 50-59 androgen receptor Homo sapiens 152-154 20807808-7 2010 Treatment of prostate cancer patients with docetaxel led to a significant translocation of AR. Docetaxel 43-52 androgen receptor Homo sapiens 91-93 20807808-8 2010 In untreated specimens, 50% prostate tumor cells exhibited nuclear accumulation of AR, compared with docetaxel-treated tumors that had significantly depleted nuclear AR (38%), paralleled by an increase in cytosolic AR. Docetaxel 101-110 androgen receptor Homo sapiens 166-168 20807808-8 2010 In untreated specimens, 50% prostate tumor cells exhibited nuclear accumulation of AR, compared with docetaxel-treated tumors that had significantly depleted nuclear AR (38%), paralleled by an increase in cytosolic AR. Docetaxel 101-110 androgen receptor Homo sapiens 166-168 20807808-12 2010 Our findings show that in addition to blocking cell division, docetaxel impairs AR signaling, evidence that enables new insights into the therapeutic efficacy of microtubule-targeting drugs in prostate cancer. Docetaxel 62-71 androgen receptor Homo sapiens 80-82 19947927-0 2010 A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line. Docetaxel 109-118 androgen receptor Homo sapiens 57-74 20419056-3 2010 We have demonstrated recently that Taxol (paclitaxel and its semisynthetic analogue docetaxel) treatment of 22Rv1, a CRPC cell line that expresses the tumor suppressor gene PTEN, inhibits AR transcriptional activity. Docetaxel 84-93 androgen receptor Homo sapiens 188-190 19826044-3 2009 Here, we showed that treatment of 22Rv1, a PTEN-positive CRPC cell line, with paclitaxel and its semisynthetic analogue docetaxel decreases expression of the androgen receptor (AR)-activated genes prostate-specific antigen (PSA) and Nkx3.1 but increases expression of the AR repression gene maspin, suggesting that Taxol treatment inhibits AR activity. Docetaxel 120-129 androgen receptor Homo sapiens 158-175 19826044-3 2009 Here, we showed that treatment of 22Rv1, a PTEN-positive CRPC cell line, with paclitaxel and its semisynthetic analogue docetaxel decreases expression of the androgen receptor (AR)-activated genes prostate-specific antigen (PSA) and Nkx3.1 but increases expression of the AR repression gene maspin, suggesting that Taxol treatment inhibits AR activity. Docetaxel 120-129 androgen receptor Homo sapiens 177-179 19826044-3 2009 Here, we showed that treatment of 22Rv1, a PTEN-positive CRPC cell line, with paclitaxel and its semisynthetic analogue docetaxel decreases expression of the androgen receptor (AR)-activated genes prostate-specific antigen (PSA) and Nkx3.1 but increases expression of the AR repression gene maspin, suggesting that Taxol treatment inhibits AR activity. Docetaxel 120-129 androgen receptor Homo sapiens 272-274 19826044-3 2009 Here, we showed that treatment of 22Rv1, a PTEN-positive CRPC cell line, with paclitaxel and its semisynthetic analogue docetaxel decreases expression of the androgen receptor (AR)-activated genes prostate-specific antigen (PSA) and Nkx3.1 but increases expression of the AR repression gene maspin, suggesting that Taxol treatment inhibits AR activity. Docetaxel 120-129 androgen receptor Homo sapiens 272-274 23775496-9 2013 In addition, androgen receptor (AR) knockdown increased cellular sensitivity to docetaxel, though AR expression in docetaxel-resistant LNCaP cells was paradoxically lower than in parental cells. Docetaxel 80-89 androgen receptor Homo sapiens 13-30 23775496-9 2013 In addition, androgen receptor (AR) knockdown increased cellular sensitivity to docetaxel, though AR expression in docetaxel-resistant LNCaP cells was paradoxically lower than in parental cells. Docetaxel 80-89 androgen receptor Homo sapiens 32-34 23775496-9 2013 In addition, androgen receptor (AR) knockdown increased cellular sensitivity to docetaxel, though AR expression in docetaxel-resistant LNCaP cells was paradoxically lower than in parental cells. Docetaxel 115-124 androgen receptor Homo sapiens 98-100 23775496-11 2013 CONCLUSIONS: Twist1/YB-1 and AR signaling promote docetaxel resistance in CRPC cells. Docetaxel 50-59 androgen receptor Homo sapiens 29-31 23775496-12 2013 However, docetaxel-resistant cells were collaterally sensitive to androgen deprivation because of down-regulation of AR expression, suggesting that the therapeutic effect of initial taxane treatment in hormone-naive prostate cancer may be superior to that of salvage taxane treatment in CRPC. Docetaxel 9-18 androgen receptor Homo sapiens 117-119 23566222-0 2013 Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia. Docetaxel 37-46 androgen receptor Homo sapiens 91-108 23566222-8 2013 Interrupting Vav3 signaling using siRNA enhanced docetaxel-induced cell growth suppression compared with that induced by docetaxel alone by inhibition of Akt and ERK phosphorylation, resulting in AR phosphorylation inhibition. Docetaxel 49-58 androgen receptor Homo sapiens 196-198 23076185-0 2012 [Effect of docetaxel on C-jun and androgen receptor interaction in prostate cancer LNCaP cells and its androgen-independence subtype LNCaP-bic cells]. Docetaxel 11-20 androgen receptor Homo sapiens 34-51 23076185-1 2012 OBJECTIVE: To investigate the effect of docetaxel on the interaction between C-jun and androgen receptor (AR) in prostate cancer LNCaP cells and its androgen-independence subtype LNCaP-bic cells. Docetaxel 40-49 androgen receptor Homo sapiens 87-104 23076185-1 2012 OBJECTIVE: To investigate the effect of docetaxel on the interaction between C-jun and androgen receptor (AR) in prostate cancer LNCaP cells and its androgen-independence subtype LNCaP-bic cells. Docetaxel 40-49 androgen receptor Homo sapiens 106-108 23076185-3 2012 Western blotting and immunoprecipitation assay were employed to analyze the effects of docetaxel on the expressions of C-jun and AR and their interaction. Docetaxel 87-96 androgen receptor Homo sapiens 129-131 23076185-7 2012 Docetaxel caused a stronger interaction between AR and C-jun in LNCaP-bic cells. Docetaxel 0-9 androgen receptor Homo sapiens 48-50 23076185-8 2012 CONCLUSION: Docetaxel activates ligand-independent AR transcription, and the interaction between AR and C-jun may affect the outcome of docetaxel chemotherapy. Docetaxel 12-21 androgen receptor Homo sapiens 51-53 23076185-8 2012 CONCLUSION: Docetaxel activates ligand-independent AR transcription, and the interaction between AR and C-jun may affect the outcome of docetaxel chemotherapy. Docetaxel 136-145 androgen receptor Homo sapiens 97-99 19575420-0 2009 Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Docetaxel 0-9 androgen receptor Homo sapiens 43-60 19575420-8 2009 Unexpectedly, we found DOC significantly down-regulated both AR and PSA in a dose-dependent manner in the cell lines studied. Docetaxel 23-26 androgen receptor Homo sapiens 61-63 19575420-9 2009 Over-expression of AR partially abrogated the cytotoxic effects of DOC. Docetaxel 67-70 androgen receptor Homo sapiens 19-21 18726991-5 2008 Here, we report that a variety of chemotherapeutic agents, including proteasome inhibitors, a topoisomerase inhibitor, DNA-damaging agents and docetaxel that cause cell death, decrease AR levels in LNCaP prostate cancer cells. Docetaxel 143-152 androgen receptor Homo sapiens 185-187 34672379-3 2022 In contrast, when DTX is deployed with androgen deprivation therapy in castration-sensitive disease, more durable responses and improved outcomes are observed, suggesting that aberrant androgen receptor (AR) signaling accelerates DTX resistance in CRPC. Docetaxel 18-21 androgen receptor Homo sapiens 185-202 34672379-3 2022 In contrast, when DTX is deployed with androgen deprivation therapy in castration-sensitive disease, more durable responses and improved outcomes are observed, suggesting that aberrant androgen receptor (AR) signaling accelerates DTX resistance in CRPC. Docetaxel 18-21 androgen receptor Homo sapiens 204-206 34672379-3 2022 In contrast, when DTX is deployed with androgen deprivation therapy in castration-sensitive disease, more durable responses and improved outcomes are observed, suggesting that aberrant androgen receptor (AR) signaling accelerates DTX resistance in CRPC. Docetaxel 230-233 androgen receptor Homo sapiens 185-202 34672379-3 2022 In contrast, when DTX is deployed with androgen deprivation therapy in castration-sensitive disease, more durable responses and improved outcomes are observed, suggesting that aberrant androgen receptor (AR) signaling accelerates DTX resistance in CRPC. Docetaxel 230-233 androgen receptor Homo sapiens 204-206 34672379-4 2022 In this study, we demonstrate that AR dysregulates the mitotic checkpoint, a critical pathway involved in the anticancer action of DTX. Docetaxel 131-134 androgen receptor Homo sapiens 35-37 34672379-5 2022 METHODS: Androgen-dependent and independent cell lines were used to evaluate the role of AR in DTX resistance. Docetaxel 95-98 androgen receptor Homo sapiens 89-91 34672379-10 2022 RESULTS: Activation of AR in hormone-sensitive cells induces a rescue phenotype by increasing cell viability and survival and attenuating G2/M arrest in response to DTX. Docetaxel 165-168 androgen receptor Homo sapiens 23-25 34672379-15 2022 CONCLUSION: Our results suggest that targeting the mechanisms of dysregulated mitotic checkpoint signaling in AR-reactivated tumors has significant clinical potential to extend treatment benefit with DTX and improve outcomes in patients with lethal prostate cancer. Docetaxel 200-203 androgen receptor Homo sapiens 110-112 34322995-8 2021 Furthermore, inhibition of JAK1/2 by baricitinib and ruxolitinib synergizes docetaxel sensitivity in both androgen receptor (AR)-negative DU145 and PC3 cells, but not in the AR-positive LNCaP cells. Docetaxel 76-85 androgen receptor Homo sapiens 106-123 34322995-8 2021 Furthermore, inhibition of JAK1/2 by baricitinib and ruxolitinib synergizes docetaxel sensitivity in both androgen receptor (AR)-negative DU145 and PC3 cells, but not in the AR-positive LNCaP cells. Docetaxel 76-85 androgen receptor Homo sapiens 125-127 35631549-4 2022 Thus, to optimize DTX efficacy, continued maximum suppression of androgen levels and AR signaling is required. Docetaxel 18-21 androgen receptor Homo sapiens 85-87 35631549-6 2022 Specifically, DTX was encapsulated into the hydrophobic inner layer, and the AR siRNA was then condensed with the cationic PEI block in the hydrophilic outer layer of the PEI-PLGA polymeric micelles. Docetaxel 14-17 androgen receptor Homo sapiens 77-79 34358777-1 2021 BACKGROUND: Pre-clinical data suggest that docetaxel and enzalutamide interfere with androgen receptor translocation and signalling. Docetaxel 43-52 androgen receptor Homo sapiens 85-102 35227076-5 2022 AR- status predicted the failure of adjuvant endocrine therapy with aromatase inhibitors and of adjuvant chemotherapy with docetaxel plus cyclophosphamide. Docetaxel 123-132 androgen receptor Homo sapiens 0-2 35220240-1 2022 BACKGROUND/AIM: To assess the efficacy of novel therapeutic agents, such as androgen receptor axis-targeted agents (ARATs) and cabazitaxel, for relapse of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel in real-world practice, we performed a subanalysis using database from PROSTAT-BSI, a prospective observational study to evaluate the utility of software for quantifying bone metastases on bone scintigraphy. Docetaxel 217-226 androgen receptor Homo sapiens 76-93